RxDoctor Payments Data

Timothy Goshen, DO

Colorectal Surgery (Proctology) · Wilton Manors, FLNPI 1083665723

Payments from drug & device makers

$2,093in general payments, 2019–2025

Across 75 payments — averaging $27.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$886
  • Janssen Products, LP$451
  • Viiv Healthcare Company$364
  • Johnson & Johnson$270
  • Galderma Laboratories, L.p.$102
  • Phathom Pharmaceuticals, Inc.$21

What the payments were for

  • Food & beverage$1,99495%
  • Education$995%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few colorectal surgery (proctology) providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$57,421
Medicare patients
110
Services billed
460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrezcobixDarunavir/Cobicistat61$152,670
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf16$81,597
DescovyEmtricitabine/Tenofov Alafenam25$57,734
BiktarvyBictegrav/Emtricit/Tenofov Ala12$45,576
TivicayDolutegravir Sodium16$35,781
Etravirine11$14,063
EliquisApixaban11$10,367
JanuviaSitagliptin Phosphate12$6,916
Testosterone16$2,909
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)15$2,670
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates14$867
CholestyramineCholestyramine (With Sugar)19$573
Albuterol Sulfate HfaAlbuterol Sulfate12$321
Rosuvastatin Calcium21$313
Atorvastatin Calcium34$249

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonPrezcobix$270$152,67061 claims
GileadDescovy, Biktarvy$886$103,30937 claims
Janssen Products, LPSymtuza$451$81,59716 claims
Viiv Healthcare CompanyTivicay$364$35,78116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few colorectal surgery (proctology) providers in Floridaon file to place this against a meaningful peer group, so we don't.

Other colorectal surgery (proctology) in Wilton Manors

Where these figures come from

Is this you, or does something look wrong? →